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Autism spectrum disorders (ASD) is a heterogenous 
group of neurodevelopmental disorders, the 
etiology or etiologies of which remain unknown1. 
The autistic disorder is defined entirely based on 
the impairment in three areas: 1) Impairment of 
social interaction, 2) Impairment in communication 
and, 3) Stereotyped and repetitive behavior2. 
Autism is a lifelong neurodevelopmental disorder 
characterized by social deficits, impaired verbal and 
nonverbal communication and the presence of 
stereotyped behaviors or circumscribed interests3. 
Autism, Rett syndrome together, with Asperger 
syndrome and pervasive developmental disorder not 
otherwise specified, referred to as autism spectrum  
 
 
disorders (ASD) that  form a spectrum of conditions 
with varying degrees of impairment that are 
classified as pervasive developmental disorders in 
the DSM-IV4. The current estimate of prevalence of 
autism spectrum disorder is approximately 1:1505. 
There are many causes of autism that will likely 
have varying contributions from genetic and 
environmental factors6. One persistent suggestion 
has been that an immune dysfunction may 
contribute to certain forms of autism7. Increasing 
evidence of autoimmune phenomena in individuals 
with autism could represent the presence of altered 
or inappropriate immune responses in this disorder, 
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immune system and neuronal system/brain, and that normal neurodevelopment is 
contingent upon an appropriate interaction with the immune system. Objectives: the 
aim of the present study was to evaluate the cell mediated and humoral immunity of 
children with autism through evaluation of the serum antibody levels of 
immunoglobulin (IgG, IgM, IgA), also we evaluated the T helper and T suppressor 
cells (CD4 and CD8 T cell subpopulations) and CD4/CD8 ratio in children with 
autism and compared with the healthy control children. Methods: This study was 
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Hospital. Thirty children with autism (24 males, 6 females) newly diagnosed were 
included in the study, their age range was (3-9 years) with the mean age of 51.8 
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IgM compared to the control children p0.001. Also children with autism had 
significantly lower numbers of CD4 cells with increased CD8+ T cell 
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autism  have significantly reduced levels of serum IgG, IgA  and IgM compared to 
the control children, suggesting an underlying defect in the immune function, also 
the cell-mediated immunity is impaired as evidenced by low numbers of CD4+ cells 
and increased  CD8+ T cell subpopulations and  decreased CD4+/CD8+ ratio.   
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and this immune system dysfunction may represent 
novel targets for treatment8. 
There have been numerous findings of altered 
immune function in autism, numerous attempts at 
determining susceptibility genes through a number 
of studies have indicated that multiple genes, 
including immune related genes, may be associated 
with autism9,10. Studies have highlighted the 
presence of inflammation in the brain and the 
activation of microglia as well as evidence for 
altered peripheral immune function in autism, 
including increased cytokine levels in the plasma 
such as interleukin IL-1β, IL-6, and IL-8, elevated 
levels of complement proteins, decreased cellular 
activity of natural killer (NK) cells, increased 
monocyte activation, and a reduced number of 
CD4+ T cells11. In addition, a number of studies 
have reported abnormal antibody responses to brain 
and central nervous system proteins, skewed 
immunoglobulin (Ig) responses, such as decreased 
total serum IgG levels but increased isotype IgG4, 
have also been reported in autism12.  The immune 
system is made up of several different parts; B-cells 
produce antibodies or immunoglobulins, T-cells are 
the cells involved in what is called cellular 
immunity13. The functions of the T-cells are to kill 
foreign tissue or tissues infected with virus, to 
produce lymphokines, which are large proteins that 
regulate other cells of the immune system and to 
help to enhance the immune response14. The 
complement system is a group of proteins involved 
as a nonspecific helper to the immune system. The 
phagocytic cells include cells called macrophages 
and neutrophils that engulf bacteria and yeast and 
digest them15. Most of the T cells in the body 
belong to one of two subsets. These are 
distinguished by the presence on their surface of 
one or the other of two glycoproteins designated: 
CD4 and CD816. CD4+ T cells bind an epitope 
consisting of an antigen fragment lying in the 
groove of a class II histocompatibility molecule. 
CD4+ T cells are essential for both the cell-
mediated and antibody-mediated branches of the 
immune system CD4 cells or helper T cells provide 
protection against different pathogens17. CD8+ T 
cells are cytotoxic T lymphocytes (CTLs). They 
secrete molecules that destroy the cell to which they 
have bound18. Cell-mediated immunity includes, 
CD4+ cells that bind to antigen presented by 
antigen-presenting cells (APCs) like phagocytic 
macrophages and dendritic cells. The T cells then 
release lymphokines that attract other cells to the 
area . The result is inflammation and accumulation 
of cells and molecules that attempt to wall off and 
destroy the antigenic material19,20.  
The aim of the present study was to evaluate 
the immune system including cell mediated and 
humoral immunity of children with autism in 
attempt to determine if immune mechanisms are 
involved in the development of autism, through 
evaluation of the immunoglobulins (IgG, IgM, IgA) 
serum levels. Also, the T helper and T suppressor 
cells (CD4 and CD8 T cell subpopulations) and 
CD4/CD8 ratio  in children with autism, to 
investigate the possibility that immune 
abnormalities in some children with autism may 
involve abnormal distributions of CD4+ and/or 
CD8+ cells, (suppressor) T cells and compare them 
with the healthy control children. 
 
METHODS 
This study was carried out in Tanta University 
Hospital, Pediatric Department, Psychiatry Unit. 
Thirty children newly diagnosed as autism (24 
males, 6 females) were included in the study, their 
age range was (3-9 years), with the mean age of 
51.8 years. The intial Childhood Autism Rating 
Scale (CARS) score for these children was 30. 
Children with a CARS score 30 were considered 
to have autism21.  The intial CARS score range for 
children with autism  was (31-60). Children with 
CARS score range (31-37) were considered to have 
moderate autism and their number was 16 children 
and children with CARS range 37-60 were 
diagnosed as severe autism, their number was 14 
children. The exclusion criteria for all subjects 
consisted of the presence of children who had 
clinical features of Fragile X-disorder, tuberous 
sclerosis and phenylketonuria , severe organic 
condition, presence of epilepsy or other severe 
neurological disorder . Children with pervasive 
developmental disorder-not otherwise specified 
(PDD-NOS) or Asperger Syndrome were excluded 
from the study. Children with known endocrine, 
cardiovascular, pulmonary, liver or kidney disease 
were excluded from study. The blood samples were 
taken before the start of any treatment . The control 
group consisted of thirty healthy children (10 
females, 20 males). Their age range was (2-10 
years) and the mean age was 5.3 2.4 years. They 
had no history or family history of any psychiatric 
disorder. The control children were matched with 
the patients as regards to sex and age.   All children 
were included in the study after written informed 
parental consent had been obtained .The study was 
approved by the local ethics committee of the 
Faculty of Medicine Tanta University. Full history 
was taken including, medical history, family 
history, birth history, early development and history 
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of recurrent infections. Also physical examination 
including complete neurological examination for all 
children.  Mental status examination included the 
evaluation of social interaction, language and 
communicative functions. Childhood Autism 
Rating Scale (CARS) was applied for children with 
autism to assess its severity. CARS is a diagnostic 
assessment method that rates children on a scale 
from one to four for various criteria, ranging from 
normal to severe, and yields a composite score 
ranging from non-autistic to mildly autistic, 
moderately autistic, or severely autistic. The scale is 
used to observe and subjectively rate fifteen items, 
these items are:  relationship to people, imitation, 
emotional response, body use, object use, 
adaptation to change, visual response, listening 
response, taste-smell-touch response and use, fear 
and nervousness, verbal communication, non-verbal 
communication, activity level, level and 
consistency of intellectual response . This scale was 
completed by the clinician, based on subjective 
observations of the child's behavior. Each of the 
fifteen criteria is rated with a score of :1 normal for 
child’s age, 2 mildly abnormal, 3 moderately 
abnormal , 4 severely abnormal. Total CARS scores 
range from a 15 to 60, with a minimum score of 30 
serving as the cutoff for a diagnosis of autism21. 
Also hearing test include, Auditory Brain Stem 
Response (ABR) for children with autism was 
done. Electroencephalography (EEG) was done  for 
autistic children. Brain Magnetic Resonance 
Imaging (MRI) was done for autistic children to 
exclude children with structural lesion or tuberous 
sclerosis. Complete blood count including cell 
count for the major immune cell populations i.e., 
neutrophils, lymphocytes, eosinophils, monocytes 
and platelets. Other routine laboratory tests, 
including, liver function, kidney function and 
fasting blood sugar were done for all children. 
Serum  antibody levels of immunoglobulins (IgG, 
IgM, IgA) also T helper and T suppressor cells 
(CD4 and CD8 T cell subpopulations) and 
CD4/CD8 ratio were assayed in all included 
children. 
 
Sample Collection:  
Ten milliliters of blood single sample  from each 
child was collected in yellow top citrate tubes (BD 
Biosciences, Franklin Lakes, NJ) according to the 
study protocol and divided into two equal parts; 5 
ml were centrifuged at a rate 3000 round per minute 
for 10 min to separate the serum which was 
collected and immediately frozen in 0.5 ml aliquots 
at -80°C until assayed for  Ig levels by ELISA , and 
the other 5 ml were used as a fresh samples for the 
procedure of flow cytometry which is performed 
according to the procedure mentioned below. 
 
Assessment of systemic level of immunoglobulins 
by ELISA: 
Levels of total IgG, IgM and IgA, were determined 
by enzyme-linked immunosorbent assay (ELISA) 
using commercially available kits purchased from 
ALerCHEK Inc. (Portland, ME). Kits were run 
according to the manufacturer’s instructions as 
described previously . Briefly, serum samples were 
diluted 1:100,000 (IgG), 1:10,000 (IgM and IgA), 
or 1:10 (IgE) and added to 96 well plates pre-coated 
with capture antibody. After 1-hr incubation and 
subsequent washing, horseradish peroxidase- 
conjugated detection antibodies were added and 
TMB (3,3′, 5,5′ tetramethyl benzidine)/peroxide 
substrate used for development. Data are reported 
as median mg/mL (IgG, IgM, IgA) . Intra- and 
inter-assay variability was controlled for using 
control standards on each plate. The coefficient of 
variance was less than 10% on any given plate22. 
 
Flow cytometric analysis 
Flow cytometry of lymphocyte subsets was carried 
out using a lamp-based flow cytometer (Bryte-HS, 
Bio-Rad, Hercules, Calif.) according to the 
manufacturer's instructions. White blood cell 
counting and differentiation were performed using a 
Symex-SF3000 Coulter counter (Coulter Electronic, 
Luton, London). Samples were then stained using 
OptiClone CD4/CD8, immunoglobulin G1-
fluorescein isothiocyanate, and immunoglobulin 
G1-phycoerythrin monoclonal antibodies (Coulter-
Immunotech, Miami, Florida). The monoclonal 
antibodies, 13B8.2 and B9.11, were used to bind 
specifically to CD4 and CD8 subsets of peripheral 
blood T lymphocytes, respectively. The 
determination of positive and negative cells for any 
combination of reagents was set with directly 
conjugated antibodies of irrelevant specificity as 
negative controls. Positive and negative controls 
were included in each run according to guidelines 
issued previously . Percentages of CD8+ and CD4+ 
cells were measured with Coulter software, and 
CD4/CD8 ratios were calculated23.  
 
Statistical Analysis 
Collected data were coded, analyzed and computed 
using the Statistical Package for Social Sciences 
(SPSS) version 10. Results were expressed as mean 
SD, and differences between the means of 
different variables were tested using the student t-
test. Differences were considered significant 
statistically when p 0.05.  
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RESULTS 
Table (1) represents characteristics of children with 
autism and the control children. Table (2) and 
figure (1) show comparison between the mean 
serum concentrations of the immunoglobulins (IgG, 
IgM, IgA) in children with autism and the control 
children. Children with autism had significantly 
reduced serum levels of IgG, IgM and IgA  in 
comparison to the healthy control children P0.001. 
Table (3) and figure (2) show comparison between 
the mean  percentage of the T helper and T 
suppressor cells (CD4 and CD8) T cell 
subpopulations and CD4/CD8 ratio  in children 
with autism and the control children. Children with 
autism had significantly reduced levels of T helper 
(CD4) T cell subpopulations and increased levels of 
the T suppressor (CD8) T cell subpopulations  and 
reduced CD4/CD8 ratio in comparison to the 
control children  P0.001. Figure (3) shows 
significant negative correlation between the severity 
of autism and CD4/CD8 ratio, where increased 
CARS score is associated with decreased CD4/CD8 








































P value  significant 0.05 
 
 
Table 2. Comparison for mean serum concentrations of Immunoglobulins (IgG, IgM, IgA) between children 


















































P value  significant 0.05 
 
 
Table 3.  Comparison for mean  percentage of  CD4, CD8  T Cell Subpopulations and CD4/CD8 ratio 
between children with Autism and the control children. 

















































P value  significant 0.05 
























Figure 1.  Mean Serum Concentrations of 
Immunoglobulins (IgG, IgM, IgA) in Children with Autism 
and the Control Children. 
Figure 2. Mean Percentage of The CD4, CD8  T 
Cell Subpopulations and CD4/CD8 Ratio in 
Children with Autism and The Control Children. 
 

































r=0.849              P value 0.001 




Autism is a generalized or pervasive developmental 
disorder that affects about five in ten thousands of 
children worldwide (5/10.000), with a ratio of 
male/female, 4:124,25. Autism spectrum disorder is 
of interest neurochemically because it represents a 
relatively homogeneous disorder with regard to 
disease development, abnormal cognitive 
development and intellectual development26. A 
potential etiologic role for immune dysfunction in 
autism has been suggested, disturbance in the 
immune function can detrimentally influence early 
brain development 27. 
Our work revealed significantly reduced levels 
of the serum IgG, IgM and IgA in children with 
autism compared to the controls, suggesting an 
underlying defect in immune function with 
impaired humoral immunity in autism. The results 
of this study agree with those obtained by Heuer et 
al.28, who found significantly reduced  plasma 
levels of immunoglobulins (IgG, IgM, IgA). 
Immunoglobulin production is the end result of B-
cell activation generated during an immune 
response and decreased levels are indicative of an 
immune defect29. Research has implicated 
immunological, neurological, genetic, and 
environmental factors as possible contributors to 
Abd El-Aziz and Alam El-Din 
  30
this complex disorder, and a correlation between 
decreased levels of immunoglobulin (Ig) and 
behavioral outcome had been reported  in children 
with autism30. Immune-system abnormalities may 
be directly related to underlying biologic processes 
of autism, or these changes may be an indirect 
reflection of the actual pathologic mechanism , thus 
identification of the immune defect responsible for 
reduced immunoglobulin production may provide 
insight into common affected pathways in 
neurodevelopment31. 
Our study had also revealed that, children with 
autism had impaired cell mediated immunity as 
evidenced by low numbers of CD4 T cells with an 
increased CD8 T cell with decreased CD4/CD8 
ratio in comparison to the control children. A 
previous study of autistic patients revealed several 
immune-system abnormalities, including decreased 
numbers of T lymphocytes; and an altered ratio of 
helper to suppressor T cells32. Our results agree 
with Ashwood et al.33; Who assessed the cellular 
immune function in 66 children with a confirmed 
diagnosis of autism and compared them with 73 
confirmed typically developing normal controls and 
had found that,  the frequency of CD4+ and CD8+ 
T cells were significantly reduced in children with 
autism but we found increased level of CD8+ T cell 
subset. Our results also agree with the results 
obtained by Yonk et al.34; who had studied the 
CD4+ and/ CD8+ T cells, and the  peripheral blood 
lymphocytes of 25 autistic children and had found 
that, autistic children  had a significantly lower 
percentage and number of CD4+ cells, and 
increased number of CD8+ T cells and a lower 
percentage and number of total lymphocytes than 
the  normal subjects. Depressed in-vitro response to 
mitogens and recall antigens and decreased 
proportions of CD3, CD4 and increased CD8 T 
cells was reported. Patients with autism have been 
shown to have decreased intracellular interferon  
and inteleukin (IL)-2 containing CD4 T cells, 
whereas IL-4 containing are increased35. 
The present work revealed negative correlation 
between autism severity and CD4/CD8 ratio in 
autistic children. Evidence of an immune deficiency 
coupled with severity of behavioral measures would 
suggest a common defect in both neuro- and 
immunodevelopment36. The interface between the 
cellular immune system and the nervous system is 
exceedingly complex with extensive com-
munication occurring between them in health and 
disease. Immune cells and immune molecules, such 
as cytokines and chemokines, can modulate brain 
function, affecting cognitive and emotional 
processing, and have assorted effects on neuronal 
tissue, such as the modulation of systemic and CNS 
responses to infection, injury, and inflammation37. 
Immunological abnormalities in both the innate and 
adaptive immune system that are manifested by a 
paradox of immunodeficiency , inflammation  and 
autoimmunity  have been reported in autism . 
Immunological abnormalities include depressed 
cell-mediated immunity and antibody-mediated 
immunity, increased production of proinflammatory 
cytokines and chemokines, and the presence of 
autoantibodies against various neural tissues and 
antigens38. These neuroimmune interactions begin 
early during embryogenesis and persist throughout 
an individual’s lifetime, with successful 
neurodevelopment contingent upon a normal 
balanced immune response39. 
Defects in all parts of the immune system have 
been documented in children with autism. Children 
with autism have significantly reduced serum IgG, 
IGA and IgM levels compared to the control 
children, suggesting an underlying defect in 
immune function. Abnormal CD4/CD8 ratio may 
represent an important link between inflammatory 
processes that have reported in some children with 
autism, and could point to a specific immune basis 
for the disorder in many subjects. Taken together, 
these data are suggestive of a link between autism 
and immune dysfunction and that specific cellular 
phenotypes or activation status of immune cells 
may be altered in autism. Thus, identification of the 
immune defect responsible for reduced 
immunoglobulins production may provide insight 
into common affected pathways in 
neurodevelopment. Further investigation of cellular 
immunity profiles should be done to find the 
relationship between immune dysfunction and the 
progression of behavioral and developmental 
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